Skip to main content
. 2021 Feb 17;16:90. doi: 10.1186/s13023-021-01733-4

Fig. 3.

Fig. 3

Prevalence trend (2008–2017) of the investigated disease-modifying antirheumatic drugs (DMARDs): azathioprine, cyclophosphamide, ciclosporin, methotrexate, hydroxychloroquine, mycophenolic acid (as mycophenolate mofetil), and rituximab